drugset / Trial / NCT03533387

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

NCT03533387

Phase 1 Completed 28 enrolled MediciNova
RandomizedCrossoverOpen-labelOther

Summary

To compare the bioavailability and pharmacokinetic profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers

Timeline

Start
2018-04-11
Primary completion
2018-07-06
Completion
2018-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibudilast Small molecule 10 mg Oral
Subject Ibudilast Small molecule 25 mg Oral
Subject Ibudilast Small molecule 50 mg Oral

Indications

No indication recorded.